¼º°¨¿°Áõ Áø´Ü ½ÃÀå : Áúº´ À¯Çüº°, Áø´Ü Å×½ºÆ® À¯Çüº°, ±â±âº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Sexually Transmitted Disease Diagnostics Market, By Disease Type, By Diagnostic Test Type, By Device, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1514919
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 366 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¼º°¨¿°Áõ Áø´Ü ½ÃÀå ±Ô¸ð´Â 2023³â 923¾ï 4,534¸¸ ´Þ·¯·Î 2024³âºÎÅÍ 2032³â±îÁö CAGR 5.5%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼º°¨¿°Áõ Áø´Ü ½ÃÀåÀÇ ½ÃÀå ¿ªÇÐ

¼ºº´ ¹ßº´·ü Áõ°¡¿Í POC(Point of Care) µî Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î ½ÃÀå ¼ö¿ä ÃËÁø Àü¸Á

¼º°¨¿°Áõ Áø´Ü ½ÃÀåÀº Àü ¼¼°èÀûÀ¸·Î ¼ºº´ À¯ÇàÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Å©°Ô °ßÀεǰí ÀÖ½À´Ï´Ù. ¼ºº´ÀÇ ÀüÆÄ´Â ¼ºÇàÀ§ÀÇ º¯È­, ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼º ÀúÇÏ, ³·Àº ÀÎ½Ä µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÃËÁøµË´Ï´Ù. Áø´Ü °Ë»çÀÇ Çʿ伺Àº ¼ºº´¿¡ ´ëÇÑ Á¤±âÀûÀÎ °ËÁøÀ» Àå·ÁÇÏ´Â °øÁß º¸°Ç ³ë·Â°ú ÀÎ½Ä °³¼± Ä·ÆäÀο¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °Ë»ç ¹× Ä¡·á¿¡ ´ëÇÑ Æí°ßÀÌ ¿ÏÈ­µÇ¸é »ç¶÷µéÀÌ °Ë»ç ¼­ºñ½º¸¦ ¹ÞÀ» °¡´É¼ºÀÌ ³ô¾ÆÁý´Ï´Ù. Á¤ºÎ ±â°ü°ú ºñ¿µ¸® ´Üü´Â Á¶»ç Áö¿ø, °ËÁø ÇÁ·Î±×·¥ ½Ç½Ã, Áø´Ü °Ë»ç¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø µîÀ» ÅëÇØ ¼ºº´ ¿¹¹æ ¹× °ü¸® ´ëÃ¥À» ÀÚÁÖ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¿øÀº °Ë»ç ¼­ºñ½ºÀÇ Á¢±Ù¼ºÀ» ³ôÀÌ°í ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

½Å¼ÓÁø´Ü°Ë»ç(RDT), ÇöÀåÁø´Ü°Ë»ç(POCT), ÇÙ»êÁõÆø°Ë»ç(NAAT) µî Áø´Ü±â¼úÀÇ ¹ßÀüÀ¸·Î ¼º°¨¿°Áõ Áø´ÜÀÇ Á¤È®¼º, ½Å¼Ó¼º, Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÚµ¿È­¿Í ºÐÀÚÁø´ÜÇÐÀÇ ¹ßÀüÀº °Ë»ç ÀýÂ÷ÀÇ È¿À²¼ºÀ» ´õ¿í Çâ»ó½Ãŵ´Ï´Ù. ƯÈ÷ ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ°ú ¿ø°ÝÁö¿¡¼­´Â ºÐ»êÇü °Ë»ç·ÎÀÇ ÀüȯÀ¸·Î ÀÎÇØ ÇöÀå °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÈÞ´ë°¡ °£ÆíÇÏ°í »ç¿ëÇϱ⠽¬¿î Áø´Ü ±â±â¸¦ ÅëÇØ ½Å¼ÓÇÑ Áø´Ü°ú ½Å¼ÓÇÑ Ä¡·á°¡ °¡´ÉÇØÁ® ¼ºº´ÀÇ È®»êÀ» ¸·´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

¼º°¨¿°Áõ Áø´Ü ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¿¬±¸ ºÐ¼®°¡µéÀÇ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¿¬Æò±Õ ¾à 5.5%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áúº´ À¯Çüº°·Î´Â HIV/AIDS ºÐ¾ß°¡ HIV °¨¿°ÁõÀÇ È®»êÀ¸·Î ÀÎÇØ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµÇ¾ú½À´Ï´Ù.

Áø´Ü °Ë»ç À¯Çüº°·Î´Â ½ÇÇè½Ç °Ë»ç¿¡ »õ·Î¿î ±â¼úÀÌ ¸¹ÀÌ Ã¤ÅõǸ鼭 ½ÇÇè½Ç °Ë»ç ºÎ¹®ÀÌ 2023³â ÁÖ¿ä Áø´Ü °Ë»ç À¯ÇüÀ¸·Î ²ÅÇû½À´Ï´Ù.

±â±âº°·Î´Â 2023³â ½ÇÇè½Ç °Ë»ç ±â±â ºÎ¹®ÀÌ ³ôÀº ¼ö¿ä·Î ÀÎÇØ ½ÇÇè½Ç °Ë»ç ±â±â ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ÷´Ü ÇコÄÉ¾î ¼Ö·ç¼ÇÀÇ Á¸Àç·Î ÀÎÇØ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù.

¼º°¨¿°Áõ Áø´Ü ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼®:

¼¼°è ¼º°¨¿°Áõ Áø´Ü ½ÃÀåÀº Áúº´ À¯Çü, Áø´Ü Å×½ºÆ® À¯Çü, ±â±â ¹× Áö¿ªÀ» ±âÁØÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Áúº´ À¯Çü¿¡ µû¶ó Ŭ¶ó¹Ìµð¾Æ, ÀÓÁú, ¸Åµ¶, ¸Åµ¶, »ý½Ä±â Æ÷Áø, B Çü °£¿°, HIV/AIDS µî 6 °¡Áö·Î ºÐ·ùµÇ¸ç, HIV/AIDS ºÐ¾ß°¡ ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù. ¸Åµ¶, ÀÓÁú À¯º´·üÀÇ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀåÀº Áø´Ü °Ë»ç À¯Çü¿¡ µû¶ó ½ÇÇè½Ç °Ë»ç¿Í POC °Ë»ç µÎ °¡Áö·Î ³ª´¹´Ï´Ù. ½ÇÇè½Ç °Ë»ç ºÐ¾ß°¡ ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù. POC °Ë»ç´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº ±â±âº°·Î ½ÇÇè½Ç¿ë ±â±â¿Í POC¿ë ±â±â µÎ °¡Áö·Î ºÐ·ùµË´Ï´Ù. ½ÇÇè½Ç ±â±â ºÐ¾ß´Â ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È ³ôÀº ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ç÷¾× °Ë»ç ¹× ±âŸ ½Åü °Ë»ç Àåºñ¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä°¡ ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¼º°¨¿°Áõ Áø´Ü ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

Àü ¼¼°èÀûÀ¸·Î ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â ¼º°¨¿°Áõ Áø´Ü¾àÀÇ ¾ÐµµÀûÀÎ ½ÃÀåÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â ƯÈ÷ Áß±¹, Àεµ µî ½ÅÈï °æÁ¦±ÇÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡°¡ ¼º°¨¿°Áõ Áø´Ü ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °Ë»ç½Ç ¹× °Ë»ç ½Ã¼³À» Æ÷ÇÔÇÑ ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ È®´ë·Î Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

¼º°¨¿°Áõ Áø´Ü ½ÃÀå - °æÀï »óȲ:

¼º°¨¿°Áõ Áø´Ü ½ÃÀåÀº Àû´çÈ÷ ÅëÇյǾî ÀÖ½À´Ï´Ù. ½ÃÀå ÁøÀÔ ±â¾÷µéÀº ±â¼ú Çõ½Å, ½ÃÀå °³Ã´, ÆÄÆ®³Ê½Ê µî Àü·«Àû Ȱµ¿À» ÅëÇØ Á¦Ç° ¹× ¼­ºñ½º Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇϰí Àü ¼¼°è·Î ÁøÃâÇϰí ÀÖ½À´Ï´Ù. Áø´Ü ȸ»ç, ÀÇ·á ¼­ºñ½º Á¦°øÀÚ ¹× °øÁß º¸°Ç ±â°üÀÇ Çù·ÂÀº Çõ½ÅÀûÀÎ Áø´Ü ¼Ö·ç¼ÇÀÇ °³¹ß ¹× ¹èÆ÷¸¦ ÃËÁøÇÕ´Ï´Ù. ¶ÇÇÑ, ÆÄÆ®³Ê½ÊÀº ½ÃÀå µµ´Þ ¹üÀ§¸¦ ³ÐÈ÷°í À¯Åë °æ·Î¸¦ °³¼±ÇÏ´Â µ¥¿¡µµ µµ¿òÀÌ µË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼º°¨¿°Áõ Áø´Ü ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼º°¨¿°Áõ Áø´ÜÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ¼º°¨¿°Áõ Áø´Ü »ê¾÷ Á¶»ç

Á¦5Àå ¼º°¨¿°Áõ Áø´Ü ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ¼º°¨¿°Áõ Áø´Ü ½ÃÀå »óȲ

Á¦7Àå ¼º°¨¿°Áõ Áø´Ü ½ÃÀå - Áúȯ À¯Çüº°

Á¦8Àå ¼º°¨¿°Áõ Áø´Ü ½ÃÀå - Áø´Ü Å×½ºÆ® À¯Çüº°

Á¦9Àå ¼º°¨¿°Áõ Áø´Ü ½ÃÀå - µð¹ÙÀ̽ºº°

Á¦10Àå ¼º°¨¿°Áõ Áø´Ü ½ÃÀå - Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - ¼º°¨¿°Áõ Áø´Ü ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Sexually Transmitted Disease Diagnostics Market size was valued at USD 92,345.34 Million in 2023, expanding at a CAGR of 5.5% from 2024 to 2032.

Diagnostics for sexually transmitted diseases (STDs) are the several techniques and examinations used to find out if a person has a sexually transmitted infection (STI). These tests are essential for the early diagnosis, management, and control of sexually transmitted infections.

Sexually Transmitted Disease Diagnostics Market- Market Dynamics

Rising prevalence of STDs and advancement in diagnostics technologies like Point of Care (POCs) are expected to propel market demand

The market for STD diagnostics is significantly driven by the increased prevalence of STDs across the globe. The transmission of sexually transmitted diseases is facilitated by several factors, including altered sexual behavior, poor access to healthcare, and low awareness. The need for diagnostic testing is driven by public health efforts and awareness campaigns that encourage routine screening for sexually transmitted diseases. People are also more likely to seek testing services when efforts are made to lessen the stigma attached to testing and treatment. Through supporting research, putting screening programs into place, and providing financial assistance for diagnostic testing, government entities and non-profit groups frequently support STD prevention and control measures. This support makes testing services more accessible, which propels market expansion.

The accuracy, speed, and accessibility of STD diagnostics have been enhanced by developments in diagnostic technologies, such as rapid diagnostic tests (RDTs), point-of-care testing (POCTs), and nucleic acid amplification tests (NAATs). Automation and advances in molecular diagnostics increase the effectiveness of testing procedures even more. Point-of-care testing solutions are in high demand due to the shift towards decentralized testing, especially in settings with limited resources or remote locations. Rapid diagnosis and prompt treatment are made possible by portable, user-friendly diagnostic equipment, which is essential for halting the spread of STDs.

Sexually Transmitted Disease Diagnostics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.5% over the forecast period (2024-2032)

Based on Disease Type segmentation, the HIV/AIDS segment was predicted to show maximum market share in the year 2023, owing to the prevalence of HIV infections.

Based on Diagnostic Test Type segmentation, the laboratory testing segment was the leading Diagnostic Test Type in 2023, due to the high adoption of new tech at laboratory testing.

Based on Device segmentation, the laboratory devices segment was the leading Device in 2023, owing to the high demand for laboratory testing devices.

Based on region, North America was the leading revenue generator in 2023, owing to the presence of advanced healthcare solutions.

Sexually Transmitted Disease Diagnostics Market- Segmentation Analysis:

The Global Sexually Transmitted Disease Diagnostics Market is segmented based on Disease Type, Diagnostic Test Type, Device, and Region.

The market is divided into six categories based on Disease Type: Chlamydia, Gonorrhea, Syphilis, Genital herpes, Hepatitis B, and HIV/AIDS. The HIV/AIDS segment dominates the market. The growing prevalence of syphilis, gonorrhea, is also boosting the market growth.

The market is divided into two categories based on the Diagnostic Test Type: laboratory test and point of care testing. The laboratory testing segment dominates the market. The point of care testing is estimated to grow at the fastest CAGR over the forecast period.

The market is divided into two categories based on Device: laboratory devices and POC devices. The laboratory devices segment dominates the market and is expected to maintain its high dominance during the forecast period. High demand for blood tests, and other body testing devices are augmenting the segment growth.

Sexually Transmitted Disease Diagnostics Market- Geographical Insights

Globally, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America is a dominating market for Sexually Transmitted Disease Diagnostics. In Asia Pacific, the increasing healthcare spending, particularly in emerging economies like China, India, contributes to the expansion of the STD diagnostics market. Greater investment in healthcare infrastructure, including laboratories and testing facilities, improves access to diagnostic services.

Sexually Transmitted Disease Diagnostics Market- Competitive Landscape:

The sexually transmitted disease diagnostics market is moderately consolidated. Market players are involved in strategic activities like technology innovation, development, and partnerships to expand their product & service portfolio and reach across the globe. Collaboration between diagnostic companies, healthcare providers, and public health agencies facilitates the development and deployment of innovative diagnostic solutions. Partnerships can also help expand market reach and improve distribution channels.

Recent Developments:

In May 2022, Qiagen Inc. introduced NeuMoDxHSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2) with approval from the European Commission.

In May 2022, The Food and Drug Administration approved Abbott's Alinity m STI Assay for STIs.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET KEY PLAYERS

GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019-2032

GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, BY DIAGNOSTIC TEST TYPE- MARKET ANALYSIS, 2019-2032

GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, BY DEVICE- MARKET ANALYSIS, 2019-2032

GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

Table of Contents

1. Sexually Transmitted Disease Diagnostics Market Overview

2. Executive Summary

3. Sexually Transmitted Disease Diagnostics Key Market Trends

4. Sexually Transmitted Disease Diagnostics Industry Study

5. Sexually Transmitted Disease Diagnostics Market: COVID-19 Impact Analysis

6. Sexually Transmitted Disease Diagnostics Market Landscape

7. Sexually Transmitted Disease Diagnostics Market - By Disease Type

8. Sexually Transmitted Disease Diagnostics Market - By Diagnostic Test Type

9. Sexually Transmitted Disease Diagnostics Market - By Device

10. Sexually Transmitted Disease Diagnostics Market- By Geography

11. Key Vendor Analysis- Sexually Transmitted Disease Diagnostics Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â